Therapeutics

Barry Potter; Andreas H Guse; Georg W Mayr; Katrin Schweitzer

Therapeutics

Barry Potter (Inventor), Andreas H Guse (Inventor), Georg W Mayr (Inventor), Katrin Schweitzer (Inventor)

Department of Life Sciences

Research output: Patent

Abstract

The use of a compound of formula (Ia): wherein A and B are independently selected from a cyclic ring, wherein each of which cyclic rings A and B may be optionally substituted at least one ring position; and L is a suitable linker; or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in inhibiting ADP-ribosyl cyclase.

Original language	English
Patent number	WO02098397 (A2)
IPC	A61K31/7084
Publication status	Published - 12 Dec 2002

Cite this

@misc{c54dca68d4334547b1f88ce6a1719e23,

title = "Therapeutics",

abstract = "The use of a compound of formula (Ia): wherein A and B are independently selected from a cyclic ring, wherein each of which cyclic rings A and B may be optionally substituted at least one ring position; and L is a suitable linker; or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in inhibiting ADP-ribosyl cyclase.",

author = "Barry Potter and Guse, {Andreas H} and Mayr, {Georg W} and Katrin Schweitzer",

year = "2002",

month = dec,

day = "12",

language = "English",

type = "Patent",

note = "WO02098397 (A2); A61K31/7084",

}

TY - PAT

T1 - Therapeutics

AU - Potter, Barry

AU - Guse, Andreas H

AU - Mayr, Georg W

AU - Schweitzer , Katrin

PY - 2002/12/12

Y1 - 2002/12/12

N2 - The use of a compound of formula (Ia): wherein A and B are independently selected from a cyclic ring, wherein each of which cyclic rings A and B may be optionally substituted at least one ring position; and L is a suitable linker; or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in inhibiting ADP-ribosyl cyclase.

AB - The use of a compound of formula (Ia): wherein A and B are independently selected from a cyclic ring, wherein each of which cyclic rings A and B may be optionally substituted at least one ring position; and L is a suitable linker; or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in inhibiting ADP-ribosyl cyclase.

M3 - Patent

M1 - WO02098397 (A2)

ER -

Therapeutics

Abstract

Fingerprint

Cite this